Taiwanese vaccine maker Adimmune Corp. will launch clinical trials for its COVID-19 vaccine candidate in Indonesia early next year, with initial results expected in mid-2022, as it seeks to tap into the Muslim market by obtaining halal certification, the company announced on Monday.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Society
Government platform touts 60-80% reduction in statutory animal testing
04/25/2024 10:58 PM - Society
Traffic controls to be enforced at Taipei rallies Saturday
04/25/2024 10:43 PM - Society
High school student injured in earthquake dies
04/25/2024 10:31 PM - Society
Taiwan to remove points system for foreign, overseas compatriot students
04/25/2024 10:06 PM - Culture
Polaroid exhibition showcases work by influential artists, iconic cameras
04/25/2024 09:56 PM